Login / Signup

TWINGEN: protocol for an observational clinical biobank recall and biomarker cohort study to identify Finnish individuals with high risk of Alzheimer's disease.

Eero VuoksimaaToni T SaariAino AaltonenSari AaltonenSanna-Kaisa HerukkaPaula Iso-MarkkuTarja KokkolaAija KyttäläSari KärkkäinenHilkka LiedesMiina OllikainenTeemu PalviainenIlona RuotsalainenAuli ToivolaMia UrjanssonTommi VasankariHenri Vähä-YpyäMarkus M ForsbergMikko HiltunenAnu JalankoReetta KalviainenTeijo KuopioJaakko LähteenmäkiPia NybergMinna MännikköRaisa SerpiSanna SiltanenAarno PalotieJaakko A KaprioHeiko RunzValtteri Julkunennull null
Published in: BMJ open (2024)
This recall study consists of FTC/THL Biobank/FinnGen participants whose data were acquired in accordance with the Finnish Biobank Act. The recruitment protocols followed the biobank protocols approved by Finnish Medicines Agency. The TWINGEN study plan was approved by the Ethics Committee of Hospital District of Helsinki and Uusimaa (number 16831/2022). THL Biobank approved the research plan with the permission no: THLBB2022_83.
Keyphrases
  • randomized controlled trial
  • big data
  • public health
  • emergency department
  • electronic health record
  • cross sectional
  • artificial intelligence
  • adverse drug
  • mild cognitive impairment
  • data analysis